Progressive Supranuclear Palsy
113
20
30
58
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Research Maturity
58 completed trials (51% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.3%
6 terminated out of 113 trials
90.6%
+4.1% vs benchmark
3%
3 trials in Phase 3/4
12%
7 of 58 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 58 completed trials
Clinical Trials (113)
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
AMX0035 and Progressive Supranuclear Palsy
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
Community Outreach for Palliative Engagement -- Parkinson Disease
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
Art Therapy in Progressive Supranuclear Palsy
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
Automated Imaging Differentiation of Parkinsonism
The CurePSP Genetics Program
tDCS as Treatment for Motor Function
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Study of the Neural Basis of Analogical Reasoning
Speech Accessibility Project
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy